tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NAMS Stock Latest News

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Press ReleasesNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
7d ago
NAMS
NewAmsterdam Pharma reports Q1 EPS ($1.06), consensus (53c)
PremiumThe Fly
NewAmsterdam Pharma reports Q1 EPS ($1.06), consensus (53c)
7d ago
NAMS
Is NAMS a Buy, Before Earnings?
PremiumPre-Earnings
Is NAMS a Buy, Before Earnings?
12d ago
NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13d ago
NAMS
Two new option listings on May 1st
PremiumThe Fly
Two new option listings on May 1st
15d ago
AVTE
NAMS
NewAmsterdam: Enrollment met for 3 Prevail outcomes trial for ASCVD
PremiumThe FlyNewAmsterdam: Enrollment met for 3 Prevail outcomes trial for ASCVD
1M ago
NAMS
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
PremiumPress Releases
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
1M ago
NAMS
NewAmsterdam Pharma Announces Executive Leadership Changes
PremiumCompany Announcements
NewAmsterdam Pharma Announces Executive Leadership Changes
1M ago
8K
NAMS
NewAmsterdam Pharma appoints Audet as CBO
PremiumThe Fly
NewAmsterdam Pharma appoints Audet as CBO
1M ago
NAMS
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
PremiumPress Releases
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
1M ago
NAMS
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
PremiumPress Releases
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
2M ago
NAMS
Scotiabank starts NewAmsterdam at Outperform on cholesteryl-lowering agent
PremiumThe Fly
Scotiabank starts NewAmsterdam at Outperform on cholesteryl-lowering agent
2M ago
NAMS
NewAmsterdam Pharma initiated with an Outperform at Scotiabank
PremiumThe FlyNewAmsterdam Pharma initiated with an Outperform at Scotiabank
2M ago
NAMS
NewAmsterdam Pharma doses first patient in Phase 3 TANDEM trial
PremiumThe Fly
NewAmsterdam Pharma doses first patient in Phase 3 TANDEM trial
2M ago
NAMS
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
PremiumPress Releases
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
2M ago
NAMS
NewAmsterdam Pharma Updates Investor Presentation Online
PremiumCompany Announcements
NewAmsterdam Pharma Updates Investor Presentation Online
2M ago
8K
NAMS
NewAmsterdam Pharma price target raised to $31 from $25 at RBC Capital
PremiumThe Fly
NewAmsterdam Pharma price target raised to $31 from $25 at RBC Capital
3M ago
NAMS
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
3M ago
NAMS
NewAmsterdam Pharma reports Q4 EPS ($2.15), consensus ($2.11)
PremiumThe Fly
NewAmsterdam Pharma reports Q4 EPS ($2.15), consensus ($2.11)
3M ago
NAMS
NewAmsterdam Pharma Launches Public Offering for Growth
PremiumCompany AnnouncementsNewAmsterdam Pharma Launches Public Offering for Growth
3M ago
8K
NAMS
NewAmsterdam Pharma 4.49M share Spot Secondary priced at $19.00
PremiumThe Fly
NewAmsterdam Pharma 4.49M share Spot Secondary priced at $19.00
3M ago
NAMS
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
PremiumPress Releases
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
3M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >